Business
BioElectronics President Interviewed by the StockRadio.com Discusses BioElectronics, the Science of the Chronic Pain market, and Drug Use
BioElectronics President Interviewed by the StockRadio.com Discusses BioElectronics, the Science of the Chronic Pain market, and Drug Use.
About this update from Bioelectronics Corp.
[{"type":"text","content":"\n \n \n BioElectronics President Interviewed by the StockRadio.com Discusses BioElectronics, the Science of the Chronic Pain market, and Drug Use\n \n \nBioElectronics President Interviewed by the StockRadio.com Discusses BioElectronics, the Science of the Chronic Pain market, and Drug Use\n\nMr. Whelan explained the science of bioelectronics, the chronic pain market, the far-reaching product portfolio, and its award winning \"Best OTC Marketing Campaign on a Small Budget\"\n\n \n FREDERICK, MD--(Marketwired - Oct 27, 2016) -  BioElectronics Corporation (OTC PINK: BIEL), the maker of advanced nonprescription disposable $30.00 neuromodulation pain relief medical devices, is pleased to release an interview with President, Andy Whelan. The interview can be heard at http://westbrookradio.com/2016/10/26/andrew-whelan-ceo-bioelectronics-corp-biel/\n Mr. Whelan explained the science of bioelectronics, the chronic pain market, the far-reaching product portfolio, its award winning \"Best OTC Marketing Campaign on a Small Budget,\" and its assessment of 12,000+ users and the exceptional product acceptance. \n Chronic Pain - 20% of adults globally suffers from chronic pain. This market is larger than diabetes, heart disease, and cancer combined. ActiPatch is a nonprescription medical device that addresses the unmet need for 1.5 billion chronic pain sufferers worldwide that modifies the way the central nervous system works. The modification results in an increase in pain perception from less provocation. ActiPatch modulates the body's nerve activity to dampen the pain perception, thereby mitigating the use of drugs. Kenneth McLeod, Ph.D. Director of Clinical Science and Engineering Research, New York State University Binghamton's short video explains how the technology and ActiPatch work at http://actipatch.com/why-actipatch/.\n Demonstrated Marketability to Consumers - The Company's Try and Tell sales and marketing campaign has won this year's OTC Bulletin \"Best OTC Marketing Campaign on a Small Budget\" award. ActiPatch therapy is the leading analgesic in Walgreens/Boots in the UK.\n Current chronic pain therapies do not meet the need for chronic pain relief and sufferers are skeptical. To overcome the skepticism and accelerate product acceptance, we promote a discounted 7-Day Trial device without an on/off switch. 65% of test...